Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Exclusion criteria

• ✕. Total urine protein of ≥3.0g (≥3000mg) from the 24-hour urine returned at Visit 1A, AND.
• ✕. An estimated glomerular filtration rate (eGFR) value \>25mL/min/1.73m2 at Visit 1A (as calculated using the abbreviated Modification of Diet in Renal Disease \[MDRD\] equation.
• ✕. Subjects must be followed for at least 3 months after treatment prior to screening with the exception of rituximab or a cytotoxic based therapy, where the follow-up period is 6 months after treatment. If after follow-up it was determined that the subject did not achieve a complete or partial remission or suffered a relapse after achieving a partial remission, the subject will be eligible for the study.
• ✕. If in the investigator's opinion, the subject should be enrolled prior to meeting the follow-up period criteria and the decrease in proteinuria is no longer occurring, discussion between the investigator and the Medical Monitor must take place for approval to enter screening.
• ✕. Mean systolic blood pressure ≤140 mmHg and
• ✕. Mean diastolic blood pressure ≤80 mmHg.
• ✕. History of previous use of Acthar for treatment of nephrotic syndrome;
• ✕. Prior sensitivity to Acthar or other porcine protein products; or